Table 1.

Summary of commercially-available biomarkers used in clinical decision making for men with known or suspected prostate cancer.

Name	Substrate	Clinical Scenario	Outcomes Examined	Studied in Comparison with MRI?
Prostate Health Index®	Blood	Before prostate biopsy; after initial negative biopsy	Prostate cancer at biopsy	Yes
4KScore®	Blood	Before prostate biopsy; after initial negative biopsy	Prostate cancer at biopsy	Yes
ExoDX®	Urine	Before prostate biopsy; after initial negative biopsy	Prostate cancer at biopsy	No
SelectMDX ®	Urine	Before prostate biopsy; after initial negative biopsy	Prostate cancer at biopsy	No
PCA3	Urine	After initial negative biopsy	Prostate cancer at biopsy	Yes
Mi-Prostate®	Urine	Before prostate biopsy	Prostate cancer at biopsy	No
Prolaris®	Prostate cancer Tissue	After prostate cancer diagnosis or radical prostatectomy	Cancer recurrence; metastasis; death from prostate cancer	Yes
OncotypeDX ® Genomic Prostate Score (GPS)	Prostate cancer Tissue	Low and intermediate risk prostate cancer after biopsy	Adverse pathology at biopsy; cancer recurrence; metastasis; death form prostate cancer	Yes
Decipher®	Prostate cancer Tissue	After prostate cancer diagnosis or radical prostatectomy	Adverse pathology; cancer recurrence; metastasis, death from prostate cancer	Yes
Promark®	Prostate cancer Tissue	Low and intermediate risk prostate cancer after biopsy	Adverse surgical pathology	No
ConfirmMDx®	Histologically benign tissue	After negative prostate biopsy	Probability of cancer on subsequent biopsy	No